JP2011520908A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520908A5
JP2011520908A5 JP2011509721A JP2011509721A JP2011520908A5 JP 2011520908 A5 JP2011520908 A5 JP 2011520908A5 JP 2011509721 A JP2011509721 A JP 2011509721A JP 2011509721 A JP2011509721 A JP 2011509721A JP 2011520908 A5 JP2011520908 A5 JP 2011520908A5
Authority
JP
Japan
Prior art keywords
phenyl
oxo
carboxamide
dihydro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509721A
Other languages
English (en)
Japanese (ja)
Other versions
JP5699075B2 (ja
JP2011520908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044034 external-priority patent/WO2009140549A1/en
Publication of JP2011520908A publication Critical patent/JP2011520908A/ja
Publication of JP2011520908A5 publication Critical patent/JP2011520908A5/ja
Application granted granted Critical
Publication of JP5699075B2 publication Critical patent/JP5699075B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509721A 2008-05-14 2009-05-14 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ Expired - Fee Related JP5699075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12775308P 2008-05-14 2008-05-14
US61/127,753 2008-05-14
PCT/US2009/044034 WO2009140549A1 (en) 2008-05-14 2009-05-14 Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2011520908A JP2011520908A (ja) 2011-07-21
JP2011520908A5 true JP2011520908A5 (https=) 2012-06-14
JP5699075B2 JP5699075B2 (ja) 2015-04-08

Family

ID=40908799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509721A Expired - Fee Related JP5699075B2 (ja) 2008-05-14 2009-05-14 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ

Country Status (7)

Country Link
US (2) US20110104161A1 (https=)
EP (1) EP2288383A1 (https=)
JP (1) JP5699075B2 (https=)
AU (1) AU2009246263B2 (https=)
CA (1) CA2723617A1 (https=)
MX (1) MX2010012290A (https=)
WO (1) WO2009140549A1 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
TW201019961A (en) * 2008-10-17 2010-06-01 Genentech Inc Combination therapy
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
CA2800998A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
US20130315895A1 (en) * 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
JP2013540759A (ja) * 2010-09-27 2013-11-07 エクセリクシス, インク. 去勢抵抗性前立腺癌および造骨性転移の治療のためのmetおよびvegfの二元阻害薬
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
MX352926B (es) * 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
WO2012042421A1 (en) * 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
RU2568258C2 (ru) * 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
KR20120100027A (ko) * 2011-03-02 2012-09-12 한국생명공학연구원 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물
JPWO2012133416A1 (ja) 2011-03-29 2014-07-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェノキシピリジン誘導体の製造方法(3)
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ,エルエルシー 融合二環キナーゼ阻害剤
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
WO2013003606A1 (en) * 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
JP2015512447A (ja) * 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害薬の組合せおよびその使用
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
HUE032306T2 (en) 2012-06-26 2017-09-28 Bayer Pharma AG N- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides as androgen receptor antagonists, their production and use as pharmaceutical products
JP6342392B2 (ja) * 2012-07-28 2018-06-13 カリター・サイエンシーズ・エルエルシー 置換型ピラゾロン化合物及び使用方法
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
US20150299219A1 (en) * 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
JP6267619B2 (ja) * 2014-09-30 2018-01-24 学校法人近畿大学 慢性骨髄性白血病の治療用組成物
ES2749726T3 (es) * 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
EP3373932B1 (en) * 2015-11-14 2022-03-30 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
JP7208137B2 (ja) 2016-12-09 2023-01-18 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
TWI779007B (zh) 2017-01-26 2022-10-01 日商小野藥品工業股份有限公司 喹啉衍生物的乙磺酸鹽
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
WO2018151177A1 (ja) 2017-02-15 2018-08-23 大鵬薬品工業株式会社 医薬組成物
JP7128204B2 (ja) 2017-04-27 2022-08-30 アストラゼネカ・アクチエボラーグ C5-アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
JP7074760B2 (ja) 2017-09-08 2022-05-24 大鵬薬品工業株式会社 抗腫瘍剤及び抗腫瘍効果増強剤
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
CN111303024B (zh) 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
CN112778217B (zh) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 一种喹唑啉类化合物及其应用
BR112022019517A2 (pt) * 2020-03-30 2022-12-06 Hutchison Medipharma Ltd Compostos de amida e usos dos mesmos
US20230301972A1 (en) * 2020-05-20 2023-09-28 Fred Hutchinson Cancer Center Anti-fibrotic composition and related methods
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
TW202334164A (zh) 2022-01-12 2023-09-01 美商戴納立製藥公司 (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型
CN117126142B (zh) * 2023-08-30 2026-02-10 遵义医科大学珠海校区 杂环类egfr突变抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
DE102004035655A1 (de) * 2004-07-22 2006-02-16 Henkel Kgaa Verfahren zur Herstellung von Mehrphasen-Sticks für die WC-Reinigung
CA2575402A1 (en) * 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
JP2009526050A (ja) * 2006-02-10 2009-07-16 アムジエン・インコーポレーテツド Amg706の水和物形態
US8101727B2 (en) * 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Similar Documents

Publication Publication Date Title
JP2011520908A5 (https=)
CA2605680A1 (en) Substituted amide derivatives as protein kinase inhibitors
HRP20231310T1 (hr) Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
JP2008521900A5 (https=)
JP2022531801A5 (https=)
JP2023501253A5 (https=)
JP2022531932A5 (https=)
HRP20231730T1 (hr) Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
CA2587642A1 (en) Substituted heterocycles and methods of use
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
JP2019504821A5 (https=)
HRP20140265T1 (hr) Derivat aminopirazina i odgovarajuä†i lijek
MX2010012290A (es) Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
RU2014110172A (ru) Гетероциклическое производное и фармацевтическое средство
CA2671744A1 (en) Compounds and compositions as protein kinase inhibitors
JP2014062093A5 (https=)
JP2015500332A5 (https=)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
SI3074386T1 (en) New aminopyrimidine derivatives
SI3177619T1 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
JP2017530185A5 (https=)
IL295076A (en) Piperidinone derivatives as mdm2 inhibitors for cancer therapy
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
RU2014131378A (ru) Ингибиторы бромдомена